ArticlePloS one2025
The Peak Plasma Concentration (Cmax)/Minimum Inhibitory Concentration (MIC) of bedaquiline and levofloxacin with special attention to the sputum conversion in the treatment of multidrug-resistant tuberculosis in Indonesia.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberculosis in Indonesia remains a serious public health concern, as the country has the third-largest number of multidrug-resistant tuberculosis (MDR-TB) patients in the world. Bedaquiline and levofloxacin are the primary drug regimen for MDR-TB treatment in Indonesia. This study aimed to investigate whether the Cmax/MIC of bedaquiline and levofloxacin differs between patients with sputum conversion and those without sputum conversion during the first four months of MDR-TB treatment in Indonesia.
methodsA cohort study was performed in adult patients (18-65 years old) treated with the 18-24-month oral regimen. Patients were excluded if they were pregnant or HIV positive, with uncontrolled diabetes, or had any of the following severe conditions: cancer, digestive, cardiovascular system disorders, hepatic, or renal problems. Two blood samples were collected to measure the plasma concentrations of bedaquiline and levofloxacin using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Mycobacterium tuberculosis (Mtb) isolates from patients' sputum were used to determine the MIC of individual drugs using liquid growth media (MGIT).
resultsAmong the 74 patients enrolled, 16 dropped out during the four-month follow-up period. Blood samples were successfully obtained 1-2 hours after drug administration from 48 patients and 4-6 hours after drug administration from 32 patients, which were used for pharmacokinetic analysis. Sputum conversion was detected in 84.5% of patients during four months of the MDR-TB treatment. The mean Cmax/MIC ratio of bedaquiline was higher in the sputum conversion group compared with the non-conversion group (9.10 vs. 1.65, respectively). Meanwhile, a small difference in the Cmax/MIC ratio of levofloxacin was observed between the sputum conversion group and the non-conversion group; it was not significant (45.64 vs. 41.72, respectively; p = 0.941).
conclusionsCmax/MIC of bedaquiline was higher in MDR-TB patients with sputum conversion compared to those without conversion within the first four months of treatment, suggesting a potential relationship between Cmax/MIC of bedaquiline and sputum conversion, which was not seen in the levofloxacin cases. However, the application of clinical practice should be carefully considered and supported by further study in various settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.